Table 3: (a) Result of the one-day treatments. (b) Result of the three-day treatments.
(a)

TreatmentPhase I and phase II xenobiotic metabolism
[CYP] (nmol/mg)CYP2E1 (nmol/min/mg)**GST (mmol/min/mg)GSTT1 (nmol/min/mg)**

CT5
Low Dose5
Mid Dose5
High Dose5

TreatmentAntioxidant enzymes
SODGPx (U/mg)Gred (U/mg)

CT5
Low Dose5
Mid Dose5
High Dose5

TreatmentOxidative stress
[GSH] (mmol/g)[GSSG] (mmol/g)[GSH]/[GSSG]TBARS (nmol/mg)

CT5
Low Dose5
Mid Dose5
High Dose5

TreatmentGenotoxicity and proliferation
MNPCE ( )**%PCEMNHEP/1000Metaphase ( )

CT5
Low Dose5
Mid Dose5
High Dose5
Ben/DEN3

(b)

TreatmentPhase I and phase II xenobiotic metabolism
CYP (nmol/mg)**CYP2E1 (nmol/min/mg)**GST (mmol/min/mg)GSTT1 (nmol/min/mg)**

CT5
Low Dose5
Mid Dose5
High Dose5
tSBO3

TreatmentAntioxidant enzymes
SOD†**GPx (U/mg)**Gred (U/mg)**CAT (k/mg)

CT5
Low Dose5
Mid Dose5
High Dose5
CCl43

TreatmentOxidative stress
[GSH] (mmol/g)**[GSSG] (mmol/g)**[GSH]/[GSSG]**TBARS (nmol/mg)**

CT5
Low Dose5
Mid Dose5
High Dose5
CCl43

TreatmentGenotoxicity and proliferation
MNPCE ( )%PCE**MNHEP/1000Metaphase ( )**

CT5
Low Dose5
Mid Dose5
High Dose5
Ben/DEN3

Mean values plus standard deviations are presented for all the parameters.
*Positive controls significantly different from negative controls (Student -test).
**Parameters where a difference due to the treatment was found at least in one dose. Kruskal-Wallis rank test, . See text for details.
Relative units.